The Human leukocyte antigen G (HLA-G) is a non-classical, major histocompatibility complex class I (MHC-I) protein that modulates the immune response, inhibiting it in most cases. Physiologically expressed in the cells of some tissues, it increases in inflammatory reactions. Inflammation appears to play an important role in the development of chronic heart failure. This study aims to evaluate the levels of soluble HLA-G in patients with heart failure and to investigate the relationships between HLA-G and other clinical-functional parameters of the disease. Investigators hypothesize that the plasma levels of HLA-G could correlate with the clinical status of heart failure and could provide indications on patient's prognosis.
Study Type
OBSERVATIONAL
Enrollment
40
plasmatic HLA-G by blood sample
Department of Medical Sciences/ Medicine of Public Health
Ferrara, Italy
To measure plasma levels of soluble Human Leucocyte Antigen G (HLA-G) in patients with chronic heart failure (CHF)
To measure the plasmatic levels of HLA-G in patients with stable chronic heart failure at baseline. To assess possible changes in HLA-G levels, due to CHF exacerbations, at 6 and 12 months from baseline
Time frame: Collection of whole blood at baseline, at 6 and 12 months from baseline
To measure the polymorphisms of Human Leucocyte Antigen G (HLA-G) gene
To analyze the polymorphisms (Insertion/Deletion 14 pb and 3142 C\>G) of the HLA-G gene in patients with chronic heart failure (CHF) at baseline
Time frame: Collection of whole blood at baseline
To correlate the plasma levels of HLA-G with clinical-functional parameters of the chronic heart failure (CHF) in patients with CHF
To correlate plasma levels of HLA-G with Brain Natriuretic Peptide (BNP) and left ventricle ejection fraction at baseline and at 12 months from baseline
Time frame: At baseline and after 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.